

Subject name, address	Effective date	Subject name, address	Effective date	Subject name, address	Effective date	
NEWTON, KS NICHOLS, NANCY AMARILLO, TX	12/20/2005	WICHITA, KS STRAUB, ANNETTE OCALA, FL	12/20/2005	MIAMI, FL		
NOBLE, LINDA MIAMI, FL	12/20/2005	SVENDSEN, PAMELA HICKSVILLE, NY	12/20/2005	DEFAULT ON HEAL LOAN		
NOLEN, LEIGH JACKSON, TN	12/20/2005	TAIJERON, HELEN YUCCA VALLEY, CA	12/20/2005	CLARK, DOUGLAS FLORENCE, KY	12/20/2005	
NORTON, ROBERT FT PIERCE, FL	12/20/2005	TAYLOR, CAROLYN JACKSONVILLE, FL	12/20/2005	MOORE, BERNADETTE MELBOURNE, FL	12/20/2005	
OGUADIMMA, IKE CHANDLER, AZ	12/20/2005	TESCH, AARON SHEPHERDSVILLE, KY	12/20/2005	NEVAREZ-SOSTRE, EDGAR .. DORADO, PR	12/20/2005	
ONABANWO, ADENIYI CENTRAL FALLS, RI	12/20/2005	THOMPSON, ELIZABETH CORONADO, CA	12/20/2005	POLLOCK, WILLIAM AVONDALE, PA	12/20/2005	
OPATZ, KEVAN WEST PALM BEACH, FL	12/20/2005	TILLMAN, KATHERINE TUCSON, AZ	12/20/2005	RAINES, S MILTON, FL	12/20/2005	
ORENDORFF, ERIKA EXTON, PA	12/20/2005	TREAT, TARA GRENADA, MS	12/20/2005	Dated: December 7, 2005.		
OSAGIE, VICTOR MIRAMAR, FL	12/20/2005	VAUGHN, SARAH LONG BEACH, CA	12/20/2005	Katherine B. Petrowski, <i>Director, Exclusions Staff, Office of Inspector General.</i>		
OSBORNE, ANGEL ATCHISON, KS	12/20/2005	VINAGRE, ARMANDO APACHE JUNCTION, AZ	12/20/2005	[FR Doc. E5-7454 Filed 12-15-05; 8:45 am]		
OSTAD, DAVID OLD WESTBURY, NY	12/20/2005	WATTERS, YVETTE MIDDLEBURG, FL	12/20/2005	BILLING CODE 4152-01-P		
PATRICK, AMY PANAMA CITY, FL	12/20/2005	WHITE, GLYNNA LEXINGTON, KY	12/20/2005	DEPARTMENT OF HEALTH AND HUMAN SERVICES		
PECK, GREGORY QUESTA, NM	12/20/2005	WILSON, DIANE OAKLAND, CA	12/20/2005	National Institutes of Health		
PELLEY, KRISTEN YARMOUTHPORT, MA	12/20/2005	WORKMAN, REGINALD LOUISVILLE, KY	12/20/2005	Government-Owned Inventions; Availability for Licensing		
PERRONE, RUSSANNE GILBERT, AZ	12/20/2005	FRAUD/KICKBACKS/PROHIBITED ACTS/ SETTLEMENT AGREEMENTS			AGENCY: National Institutes of Health, Public Health Service, HHS.	
PERRY, TERESA EMPIRE, AL	12/20/2005	CR CENTRO MEDICO MIAMI, FL	6/1/2005	ACTION: Notice.		
PETERSON, PHYLLIS SAN FRANCISCO, CA	12/20/2005	DESTINY BILLING MIAMI, FL	6/1/2005	SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Antibodies and Immunotoxins that Target Human Glycoprotein NMB Ira Pastan (NCI) et al. U.S. Provisional Patent Application filed 31 Oct 2005 (HHS Reference No. E-003-2006/0-US-01). Licensing Contact: Jesse Kindra; 301-435-5559; kindraj@mail.nih.gov .		
PHILLIPS, MARY LEES SUMMIT, MO	12/20/2005	GACET, JAIDYS MIRAMAR, FL	6/1/2005			
PINKERTON, ROBIN PROVIDENCE, RI	12/20/2005	MOIR, LISA MORGANTON, NC	6/13/2005			
RAINES, FRANCIS LOMPOC, CA	12/20/2005	RAMOS, CELSO MIAMI, FL	6/1/2005			
RAPP, THERESA SARASOTA, FL	12/20/2005	SAOUD, ALLEN CLARKSBURG, WV	9/2/2005			
REESE, BRENT PHOENIX, AZ	12/20/2005	OWNED/CONTROLLED BY CONVICTED ENTITIES				
RICKETTS, L'PREE STURGIS, KY	12/20/2005	JONATHAN FAMILY CHIRO- PRACTIC MINNEAPOLIS, MN	12/20/2005			
RIVERA, JUAN TITUSVILLE, FL	12/20/2005	MEDICARE CENTER, LC STUART, FL	12/20/2005			
RODRIGUEZ, NORMA MIAMI, FL	12/20/2005	PAUL ELLIOT, D O, PA STUART, FL	12/20/2005			
RODRIGUEZ, SONJA VAN NUYS, CA	12/20/2005	PHYSICIANS HEALTH CARE, INC STUART, FL	12/20/2005			
ROSENDALE, GINA MULVANE, KS	12/20/2005	PHYSICIANS HEALTH MED- CARE, INC PEMBROKE PINES, FL	12/20/2005			
SAAVEDRA, JESSICA SCOTTSDALE, AZ	12/20/2005	PHYSICIANS MED-CARE, INC MIAMI, FL	12/20/2005			
SALLEE, KAREN HUMBLE, TX	12/20/2005	ROBERT J NORTON, MD, PA FT PIERCE, FL	12/20/2005			
SEGOVIA, EFRAIM MESA, AZ	12/20/2005	ST SIMONS ISLAND CLINIC, PC ST SIMONS ISLAND, GA	12/20/2005			
SESTRICH, CAROL KANSAS CITY, KS	12/20/2005	TOTAL NUTRITION, INC MIAMI, FL	12/20/2005			
SIRINEK, MATTHEW KANSAS CITY, MO	12/20/2005					
SMITH, TERESA TILINE, KY	12/20/2005					
SMITH-DEEGAN, GAIL LOS OSOS, CA	12/20/2005					
SPEARS, VIRGINIA ROSEVILLE, CA	12/20/2005					
SPENCE, TERRIE BAXTER SPRINGS, KS	12/20/2005					
STEPHENS, GRACE STEPHENS, GRACE	12/20/2005					

The human transmembrane glycoprotein NMB (GPNMB) and a splice variant form are highly expressed in the cells of several forms of brain cancer when compared to normal brain cells. This invention combines *Pseudomonas* exotoxin (PE) attached to an Fv antibody fragment that targets cells expressing GPNMB but not GPNMB-negative or normal cells. Results show that this antibody-immunotoxin conjugate inhibits the growth of cells expressing human glycoprotein GPNMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells and melanoma cells.

Method of Screening for Hepatocellular Carcinoma

Xin Wei Wang (NCI) et al.
U.S. Provisional Application filed (HHS Reference No. E-333-2005/0-US-01).
Licensing Contact: David A. Lambertson; 301-435-4632;
lambertsond@mail.nih.gov.

Hepatocellular Carcinoma (HCC) is a common and aggressive cancer with a high mortality rate. The high mortality rate stems from an inability to diagnose the cancer in patients, due to the lack of available biomarkers for HCC. Currently, HCC is diagnosed by measuring the levels of serum alpha-fetoprotein (AFP); however, AFP is not always present in HCC tumors, especially small tumors. As a result, there is a need for improved diagnostic tests for diagnosing HCC in subjects.

The instant technology relates to efficient methods of detecting HCC by using new biomarkers for HCC. The overexpression of Gpc3, Mdk, SerpinI1, PEG-10 and QP-C correlates with the presence of HCC, even in small tumors, and regardless of serum levels of AFP. By comparing the expression levels of at least three of these markers in subject samples with their expression levels in control samples, the presence of HCC can be diagnosed. The method can also be used to monitor the progression or regression of HCC in a subject after the initial diagnosis, or to identify compounds having anti-HCC activity by measuring the expression levels of Gpc3, Mdk, SerpinI1, PEG-10 and QP-C following the treatment of a sample with test compounds. Current claims are directed to methods for screening for HCC in a sample, methods for monitoring the progression or regression of HCC in a subject, methods for screening compounds as having anti-HCC activity, and arrays/kits comprising polynucleotide probes for detecting the level of Gpc3, Mdk, SerpinI1, PEG-10 and QP-C mRNA expression.

In addition to licensing, the technology (in conjunction with serum ELISA technologies) is available for further development through collaborative research opportunities with the inventors.

Mouse Polyclonal Antibodies to KAI1

Mary Custer et al. (NCI).
HHS Reference No. E-264-2005/0—
Research Tool.
Licensing Contact: John Stansberry; 301-435-5236, stansbej@mail.nih.gov.

The invention relates to polyclonal antibodies to the mouse metastasis suppressor gene KAI1. KAI1 is down regulated in advanced stages of various human epithelial malignancies. For example, expression levels of KAI1 are inversely correlated with the metastasis potential of human prostate cancer. This antibody would be useful in the characterization of the normal function of the KAI1 protein and it would be useful in efforts to investigate KAI1 role in metastasis suppression in experimental animal models.

Dated: December 8, 2005.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E5-7411 Filed 12-15-05; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Hyperaccelerated Award/Mechanisms in Immunomodulation Trials (January 2006).

Date: January 3, 2006.

Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).

Contact Person: Mercy R. PrabhuDas, Ph.D., Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 301-451-2615, mp457n@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: December 9, 2005.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05-24120 Filed 12-15-05; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Deafness and Other Communications Disorders Special Emphasis Panel, NIDCD P30 Research Core Center.

Date: January 11, 2006.

Time: 8 a.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Shiguang Yang, PhD, DVM, Scientific Review Administrator, Division of Extramural Activities, NIDCD, NIH, 6120 Executive Blvd., Bethesda, MD 20892, 301-496-8683.

Name of Committee: National Institute on Deafness and Other Communications